招商证券国际研究报告，指中生制药(01177.HK) 迈向复兴之路，是被低估的多元化大型药企。其上半年收入按年增10%，达176亿元人民币，超预期。管理层指引下半年增长提速，该行预计公司2026及27年将恢复双位数增长；又认为呼吸系统及肝病领域的增长潜力被市场低估，因公司有更优的增长前景与丰富的商业发展(BD)机会，将公司目标价上调至9.8港元，维持“增持”评级。招商证券估计，中生制药呼吸系统及...
Source Link招商证券国际研究报告，指中生制药(01177.HK) 迈向复兴之路，是被低估的多元化大型药企。其上半年收入按年增10%，达176亿元人民币，超预期。管理层指引下半年增长提速，该行预计公司2026及27年将恢复双位数增长；又认为呼吸系统及肝病领域的增长潜力被市场低估，因公司有更优的增长前景与丰富的商业发展(BD)机会，将公司目标价上调至9.8港元，维持“增持”评级。招商证券估计，中生制药呼吸系统及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.